Status:
TERMINATED
Dialysate Sodium Individualization in Hemodialysis
Lead Sponsor:
Yale University
Collaborating Sponsors:
Satellite Research
Conditions:
Hypertension
Hemodialysis Patients
Eligibility:
All Genders
18-90 years
Phase:
PHASE1
Brief Summary
Salt and water excess is an essential mechanism of hypertension. This is particularly relevant to patients with end stage kidney disease (ESKD) on dialysis. We have demonstrated that individualization...
Detailed Description
Recent evidence from our group shows that individualization of the sodium concentration in the dialysate to match the patient's own serum sodium results in less thirst, less interdialytic weight gain,...
Eligibility Criteria
Inclusion
- ESKD on hemodialysis
- Hypertension, defined as average pre-HD BP \>150/85 mmHg or use of antihypertensive drugs
- Average pre-HD serum sodium \<139 mmol/L
Exclusion
- Intradialytic hypotension
- Atrial fibrillation or other chronic tachyarrhythmia (due to effects on measuring equipment)
- Uncontrolled hypertension (average pre-HD BP \>200/105 mmHg)
- Uncontrolled diabetes mellitus (due to problems on interpretation of serum sodium values)
- Debilitating illness
- Inability to provide written informed consent
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2008
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT00259714
Start Date
March 1 2006
End Date
April 1 2008
Last Update
July 22 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Davita New Haven Dialysis Unit
New Haven, Connecticut, United States, 06520